Despite the good response to TKIs in patients with advanced and metastatic NSCLC harboring TKI‐sensitive EGFR mutations, the PFS associated with first‐generation EGFR TKI therapy (gefitinib, erlotinib) is only 8.0–13.7 months.11, 19, 23, 24, 25, 26, 27. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.